News
- Author:
- Neil Osterweil
Publish date: March 10, 2021
The disease does not respond to desmopressin, and requires von Willebrand factor concentrate with or without fact...
News
- Author:
- Neil Osterweil
Publish date: March 9, 2021
Despite girls having abnormally heavy menstrual bleeding, their families and physicians may not recognize signs o...
News
- Author:
- Neil Osterweil
Publish date: March 4, 2021
The novel antiviral was associated with a twofold improvement in CMV viremia clearance at 8 weeks of therapy ...
News
- Author:
- Neil Osterweil
Publish date: March 4, 2021
Chimeric antigen receptor T-cells are being explored for treatment of pediatric sarcomas, glioblastomas/gliomas, ...
News
- Author:
- Neil Osterweil
Publish date: February 24, 2021
Within-class comparisons can be misleading; each antihemophilia agent, old and new, needs to be evaluated separat...
News
- Author:
- Neil Osterweil
Publish date: February 23, 2021
GVHD and relapse-free survival outcomes were better with regulatory T cells given prior to stem cell transplant t...
News
- Author:
- Neil Osterweil
Publish date: February 22, 2021
The lower incidence of chronic GVHD with CD34 selection was offset by the higher mortality, compared with other G...
News
- Author:
- Neil Osterweil
Publish date: February 19, 2021
Hospitalizations related to infections and other adverse events associated with steroid use carry a high price ta...
News
- Author:
- Neil Osterweil
Publish date: February 17, 2021
Drugs with novel mechanisms of action are currently in clinical trials for chronic graft-versus-host disease.
News
- Author:
- Neil Osterweil
Publish date: February 10, 2021
In men being investigated for prostate cancer, MRI-guided targeted biopsy beat the standard approach of using tra...
News
- Author:
- Neil Osterweil
Publish date: February 9, 2021
Factor VIII concentrate is still needed to treat breakthrough bleeding in patients treated with non–factor replac...
News
- Author:
- Neil Osterweil
Publish date: February 1, 2021
The duration of response approached 4 years in some patients.
News
- Author:
- Neil Osterweil
Publish date: January 29, 2021
Adding chemoembolization to sorafenib did not improve overall survival, but the results may have been skewed by differences in post-TACE therapies....
News
- Author:
- Neil Osterweil
Publish date: January 28, 2021
Phase 3 results may provide more insight.
News
- Author:
- Neil Osterweil
Publish date: January 22, 2021
Panitumumab plus ipilimumab and nivolumab induced responses in more than a third of patients.
